Gentile, Luca
Tournev, Ivailo
Amass, Leslie
Chapman, Doug
Mazzeo, Anna
Barroso, Fabio
van Cleemput, Johan
Schmidt, Hartmut
Gess, Burkhard
Garcia Pavia, Pablo
Blanco, José Luis Muñoz
Rapezzi, Claudio
Vita, Giuseppe
Merlini, Giampaolo
Luigetti, Marco
Parman, Yesim
Maurer, Mathew
LoRusso, Samantha
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40120-021-00267-y
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
https://doi.org/10.1007/s40119-022-00265-7
Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
https://doi.org/10.1007/s40119-021-00226-6
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40119-023-00344-3
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy
https://doi.org/10.1080/13506129.2019.1643714
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology
https://doi.org/10.1185/03007995.2012.754349
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
https://doi.org/10.1185/03007995.2012.754348
Funding for this research was provided by:
Pfizer
Article History
Received: 16 April 2021
Accepted: 5 June 2021
First Online: 19 June 2021